This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate
Is Merck & Co. (MRK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Merck & Co., Inc. (MRK) Outperforming Other Medical Stocks This Year?
Top Analyst Reports for Merck, Occidental Petroleum & Capital One Financial
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Occidental Petroleum (OXY) and Capital One Financial (COF).
Gilead Collaborates with Hookipa for HBV and HIV Therapies
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.
TESARO Collaborates With Roche to Develop Zejula Combination
by Zacks Equity Research
TESARO (TSRO) collaborates with Genentech, a subsidiary of Roche, to develop Zejula in combination with an immune-oncology drug for treating ovarian cancer.
Merck Presents Positive Melanoma Data on Keytruda at ASCO
by Zacks Equity Research
Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.
Nektar (NKTR) and Bristol-Myers Present Data on Cancer Study
by Zacks Equity Research
Nektar (NKTR) and Bristol-Myers Squibb announce preliminary data from the ongoing PIVOT phase I/II study evaluating the combination of Nektar's NKTR-214 with Bristol-Myers Squibb's Opdivo.
Bristol-Myers (BMY) Reports Data from CheckMate-214 Study
by Zacks Equity Research
Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.
Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO
by Zacks Equity Research
Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.
Key FDA Events in June Investors Need to Watch Out For
by Zacks Equity Research
Investors in the healthcare industry are likely to keep a watch on upcoming PDUFA dates for key drugs in Jun 2018.
Gilead & Galapagos Announce Positive Data on Filgotinib
by Zacks Equity Research
Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.
AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why
by Zacks Equity Research
AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline
Eisai and Merck Announce Update on Lenvatinib sNDA Review
by Zacks Equity Research
Eisai/Merck's (MRK) sNDA for cancer drug, lenvatinib, seeking approval for first-line treatment of HCC gets a three-month extension from the FDA.
Merck's Keytruda Shows Survival Benefit in Squamous NSCLC
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.
Amgen's Label Expansion Application for Prolia Gets FDA Nod
by Zacks Equity Research
Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Merck, Raytheon, Eaton and Sun Life Financial
Top Analyst Reports for Home Depot, Merck & Raytheon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Merck (MRK) and Raytheon (RTN).
Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline
by Zacks Equity Research
Eli Lilly (LLY) to buy an early phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline.
Will Trump's Surprise Drug Pricing Plan Boost Pharma Stocks?
by Ritujay Ghosh
Stocks of pharmaceutical companies get a boost as Trump's proposal will actually not directly hamper their profitability.
Dow Posts Longest Stretch of Gains in 6 Months: 4 Picks
by Swarup Gupta
The index's blue chips have not looked this attractive for some time now.
Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
by David Borun
Bid U.S. drug makers are seen as largely spared the worst in the Trump Administrations plans to control drug prices.
Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall
by Zacks Equity Research
Horizon Pharma (HZNP) misses earnings and sales estimates in Q1. However, the orphan unit and the rheumatology business continue to grow.
Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down
by Zacks Equity Research
Agenus (AGEN) incurs wider-than-expected loss in Q1 and did not report any revenues during the quarter. The company expects to file six investigational new drugs in 2018.
Has Merck (MRK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is Merck & Co., Inc. (MRK) Outperforming Other Medical Stocks This Year?